Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Aug 12.

Published in final edited form as: Cancer Res. 2010 May 18;70(11):4624–4633. doi: 10.1158/0008-5472.CAN-09-3619

Table 2.

Tumor-initiating ability of CD44^pos-CD49f^hiCD133/2^hi and CD44^posCD49f^neg/lo^w-CD133/2^neg/low cells

Tumor, population	Tumor/injectison
	50	250	2,500
012 xenograft
CD44^posCD49f^hiCD133/2^hi	0/5	2/5
CD44^posCD49f^neg/lowCD133/2^neg/low	0/5	0/5
CD44^posCD49f^hi		1/3
CD44^posCD49f^neg/low		0/5
CD44^posCD133/2^hi		0/5
CD44^posCD133/2^neg/low		1/5
SH5 xenograft
CD44^posCD49f^hiCD133/2^hi	0/5	7/10	3/4
CD44^posCD49f^neg/lowCD133/2^neg/low	0/5	0/10	0/5
CD44^posCD49f^hi		9/9
CD44^posCD49f^neg/low		1/8
CD44^posCD133/2^hi		4/10
CD44^posCD133/2^neg/low		2/10
SH1 xenograft
CD44^posCD49f^hiCD133/2^hi		3/5	4/5
CD44^posCD49f^neg/lowCD133/2^neg/low		0/5	0/5
SH12 xenograft
CD44^posCD49f^hiCD133/2^hi	3/6	4/4
CD44^posCD49f^neg/lowCD133/2^neg/low	0/6	1/4
CD44^posCD49f^hi		2/5
CD44^posCD49f^neg/low		4/5
CD44^posCD133/2^hi		9/10
CD44^posCD133/2^neg/low		4/9
SH12 pleural effusion
CD44^posCD49f^hiCD133/2^hi	3/6	4/4
CD44^posCD49f^neg/lowCD133/2^neg/low	0/6	1/5